VolitionRx Submits Study on Feline Lymphoma Detection
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy VNRX?
VolitionRx announced submission for peer review a clinical manuscript reporting the accuracy of its Nu.Q Vet Feline prototype assay in detecting lymphoma in cats, the most common cancer in the species. At 97% specificity the assay detected 86% of feline lymphomas. Feline oncology lacks tumor biomarkers and so cancer in cats have been notoriously difficult to diagnose early. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5M contractual milestone payment. The Nu.Q Vet Canine test is already available in more than 20 countries.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VNRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VNRX
Wall Street analysts forecast VNRX stock price to fall
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.420
Low
1.50
Averages
2.25
High
3.00
Current: 2.420
Low
1.50
Averages
2.25
High
3.00
About VNRX
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
VolitionRx Achieves Major Milestone in Blood Testing Technology
- Technical Breakthrough: VolitionRx successfully detects nucleosomes in capillary blood from critically ill sepsis patients, marking a significant milestone for its lateral flow prototype test, which is expected to enhance early diagnostic capabilities and improve patient outcomes.
- Market Potential: The test can be utilized in emergency rooms, doctor's offices, or home self-testing, significantly expanding the market, particularly in low-income countries where there is a pressing need for rapid and convenient testing solutions.
- Strategic Partnerships: Volition plans to establish strategic collaborations with NGOs and companies operating in low-income countries to accelerate commercialization efforts and further penetrate the global market.
- Industry Impact: With approximately 166 million cases of sepsis worldwide and sepsis-related deaths accounting for 31.5% of total global deaths in 2021, the introduction of this technology is poised to transform traditional hospital infrastructure testing models and enhance healthcare efficiency.
See More
VolitionRx Receives NYSE Compliance Plan Approval
- Compliance Plan Approval: VolitionRx (VNRX) has received approval from NYSE American for its compliance plan to maintain its listing, marking a significant step in addressing its stockholder equity deficiencies.
- Historical Violation Context: The company was flagged on February 6, 2026, for failing to meet minimum stockholder equity requirements, primarily due to recurring financial losses, indicating vulnerabilities in its financial health.
- Compliance Timeline: VolitionRx submitted its compliance plan before the March 8, 2026 deadline, with the exchange granting until August 6, 2027, to regain compliance, reflecting the exchange's confidence in the company's future prospects.
- Financial Outlook: The company anticipates routine use of its Nu.Q cancer test in France by Q4 2026 while targeting a 25%-30% reduction in cash operating expenses for 2026, demonstrating its strategic intent in cost control and market expansion.
See More
VolitionRx Launches rNuQ Webshop to Expand Product Line
- Product Line Expansion: VolitionRx has launched the rNuQ webshop, offering a variety of reliable recombinant nucleosomes developed over 10 years, aimed at meeting the needs of nearly 100 global clients and accelerating disease research and drug development.
- Quality Control Advantage: All recombinant nucleosomes are manufactured in an ISO 13485 certified facility, ensuring exceptional reproducibility and quality control, simplifying handling while preserving structural integrity and enhancing experimental performance.
- Market Growth Potential: In 2025, Nu.Q® Discover achieved an 86% revenue growth, with a similar trajectory anticipated for 2026, indicating strong momentum in the company's commercialization efforts.
- Future Development Direction: VolitionRx is in discussions with several pharmaceutical companies for the bespoke development of assays, planning to expand its offerings to other biospecimens, further enhancing its market competitiveness in the biomedical field.
See More
VolitionRX Reports 133% Revenue Growth in Q4 2025
- Significant Revenue Growth: VolitionRX achieved a remarkable 133% year-on-year growth in Q4 2025, with total revenue reaching $1.7 million for the year, a 40% increase over 2024, indicating strong demand and potential market expansion in cancer detection.
- Operating Expenses Reduced: The company successfully cut operating expenses by $4.8 million, a 17% decrease compared to 2024, demonstrating effective cost control measures that enhance overall financial health.
- Cash Flow Warning: Despite revenue growth, net cash used in operating activities was $19.7 million in 2025, down from $25.9 million in 2024; however, cash and cash equivalents were only approximately $1.1 million, highlighting the urgent need for additional funding to sustain operations.
- Strategic Partnership Progress: VolitionRX signed significant agreements with Werfen and Hologic to commercialize its Nu.Q platform, marking a crucial step in the company's strategic positioning within the clinical diagnostics market, which is expected to drive future revenue growth.
See More
VolitionRx Q4 2025 Earnings Call Highlights
- New Product Orders: In Q4 2025, VolitionRx secured its first order for Nu.Q Cancer assays for clinical certification, marking a significant advancement towards routine clinical use in lung cancer, which is expected to drive future market demand and revenue growth.
- Significant Revenue Growth: The company reported full-year revenue of $1.7 million for 2025, reflecting a 40% increase, while operating expenses decreased by 17%, indicating substantial progress in cost control that will enhance profitability.
- Strategic Partnership Agreements: VolitionRx initiated its human licensing strategy by signing two agreements with Hologic and Werfen, which will help expand market reach and strengthen collaborations with industry leaders.
- Future Outlook: Although management did not provide revenue guidance for 2026, they anticipate continuing to pursue multiple licensing agreements and aim to further reduce cash operating expenses by 25%-30%, enhancing financial flexibility and market competitiveness.
See More
VolitionRX Reports 40% Revenue Growth in FY
- Fiscal Year Revenue Growth: VolitionRX reported FY revenue of $1.7 million, representing a 40% increase over the previous year, indicating the company's sustained growth potential in the competitive biotechnology sector.
- Reduced Net Loss: The company's net loss decreased by 14% compared to 2024, suggesting effective cost control measures that improve financial health and bolster investor confidence.
- Improved Cash Utilization: Cash used in operating activities was $19.7 million, down 24% year-over-year, reflecting optimization in resource allocation and operational efficiency, potentially providing more flexibility for future investments.
- Non-Dilutive Funding Secured: VolitionRX secured €2 million in non-dilutive funding from Belgian agencies, which will support its R&D and market expansion efforts, further solidifying its position in the industry.
See More
VolitionRx Achieves Major Milestone in Blood Testing Technology
- Technical Breakthrough: VolitionRx successfully detects nucleosomes in capillary blood from critically ill sepsis patients, marking a significant milestone for its lateral flow prototype test, which is expected to enhance early diagnostic capabilities and improve patient outcomes.
- Market Potential: The test can be utilized in emergency rooms, doctor's offices, or home self-testing, significantly expanding the market, particularly in low-income countries where there is a pressing need for rapid and convenient testing solutions.
- Strategic Partnerships: Volition plans to establish strategic collaborations with NGOs and companies operating in low-income countries to accelerate commercialization efforts and further penetrate the global market.
- Industry Impact: With approximately 166 million cases of sepsis worldwide and sepsis-related deaths accounting for 31.5% of total global deaths in 2021, the introduction of this technology is poised to transform traditional hospital infrastructure testing models and enhance healthcare efficiency.
See More
VolitionRx Receives NYSE Compliance Plan Approval
- Compliance Plan Approval: VolitionRx (VNRX) has received approval from NYSE American for its compliance plan to maintain its listing, marking a significant step in addressing its stockholder equity deficiencies.
- Historical Violation Context: The company was flagged on February 6, 2026, for failing to meet minimum stockholder equity requirements, primarily due to recurring financial losses, indicating vulnerabilities in its financial health.
- Compliance Timeline: VolitionRx submitted its compliance plan before the March 8, 2026 deadline, with the exchange granting until August 6, 2027, to regain compliance, reflecting the exchange's confidence in the company's future prospects.
- Financial Outlook: The company anticipates routine use of its Nu.Q cancer test in France by Q4 2026 while targeting a 25%-30% reduction in cash operating expenses for 2026, demonstrating its strategic intent in cost control and market expansion.
See More
VolitionRx Launches rNuQ Webshop to Expand Product Line
- Product Line Expansion: VolitionRx has launched the rNuQ webshop, offering a variety of reliable recombinant nucleosomes developed over 10 years, aimed at meeting the needs of nearly 100 global clients and accelerating disease research and drug development.
- Quality Control Advantage: All recombinant nucleosomes are manufactured in an ISO 13485 certified facility, ensuring exceptional reproducibility and quality control, simplifying handling while preserving structural integrity and enhancing experimental performance.
- Market Growth Potential: In 2025, Nu.Q® Discover achieved an 86% revenue growth, with a similar trajectory anticipated for 2026, indicating strong momentum in the company's commercialization efforts.
- Future Development Direction: VolitionRx is in discussions with several pharmaceutical companies for the bespoke development of assays, planning to expand its offerings to other biospecimens, further enhancing its market competitiveness in the biomedical field.
See More
VolitionRX Reports 133% Revenue Growth in Q4 2025
- Significant Revenue Growth: VolitionRX achieved a remarkable 133% year-on-year growth in Q4 2025, with total revenue reaching $1.7 million for the year, a 40% increase over 2024, indicating strong demand and potential market expansion in cancer detection.
- Operating Expenses Reduced: The company successfully cut operating expenses by $4.8 million, a 17% decrease compared to 2024, demonstrating effective cost control measures that enhance overall financial health.
- Cash Flow Warning: Despite revenue growth, net cash used in operating activities was $19.7 million in 2025, down from $25.9 million in 2024; however, cash and cash equivalents were only approximately $1.1 million, highlighting the urgent need for additional funding to sustain operations.
- Strategic Partnership Progress: VolitionRX signed significant agreements with Werfen and Hologic to commercialize its Nu.Q platform, marking a crucial step in the company's strategic positioning within the clinical diagnostics market, which is expected to drive future revenue growth.
See More
VolitionRx Q4 2025 Earnings Call Highlights
- New Product Orders: In Q4 2025, VolitionRx secured its first order for Nu.Q Cancer assays for clinical certification, marking a significant advancement towards routine clinical use in lung cancer, which is expected to drive future market demand and revenue growth.
- Significant Revenue Growth: The company reported full-year revenue of $1.7 million for 2025, reflecting a 40% increase, while operating expenses decreased by 17%, indicating substantial progress in cost control that will enhance profitability.
- Strategic Partnership Agreements: VolitionRx initiated its human licensing strategy by signing two agreements with Hologic and Werfen, which will help expand market reach and strengthen collaborations with industry leaders.
- Future Outlook: Although management did not provide revenue guidance for 2026, they anticipate continuing to pursue multiple licensing agreements and aim to further reduce cash operating expenses by 25%-30%, enhancing financial flexibility and market competitiveness.
See More
VolitionRX Reports 40% Revenue Growth in FY
- Fiscal Year Revenue Growth: VolitionRX reported FY revenue of $1.7 million, representing a 40% increase over the previous year, indicating the company's sustained growth potential in the competitive biotechnology sector.
- Reduced Net Loss: The company's net loss decreased by 14% compared to 2024, suggesting effective cost control measures that improve financial health and bolster investor confidence.
- Improved Cash Utilization: Cash used in operating activities was $19.7 million, down 24% year-over-year, reflecting optimization in resource allocation and operational efficiency, potentially providing more flexibility for future investments.
- Non-Dilutive Funding Secured: VolitionRX secured €2 million in non-dilutive funding from Belgian agencies, which will support its R&D and market expansion efforts, further solidifying its position in the industry.
See More
